ArticleESMO open2026
Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant pembrolizumab improves disease-free survival (DFS) and overall survival (OS) versus placebo in high-risk clear cell renal cell carcinoma after nephrectomy. Recently, pembrolizumab plus belzutifan showed superior DFS over pembrolizumab alone. We assessed the efficacy of adjuvant pembrolizumab plus belzutifan versus placebo using reconstructed data from two pivotal phase III trials.
methodsIndividual time-to-event data were reconstructed from digitised KEYNOTE-564 and LITESPARK-022 Kaplan-Meier curves using a validated algorithm based on numbers at risk. Datasets were pooled to enable indirect comparisons across strategies. The primary endpoint was DFS and OS was secondary. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.
findingsThe pooled dataset included 2835 patients. Baseline characteristics were balanced, except for race and programmed death-ligand 1 (PD-L1), although PD-L1 assessment was limited by incomplete reporting. Pembrolizumab plus belzutifan significantly improved DFS versus placebo (HR 0.55, 95% CI 0.45-0.69, P < 0.001). Despite immature OS data, the combination showed an OS benefit over placebo (HR 0.56, 95% CI 0.35-0.89, P = 0.014).
conclusionsAdjuvant pembrolizumab plus belzutifan showed a substantial DFS benefit compared with placebo. In a context where factors beyond efficacy demand robust evidence of clinical benefit, these findings reinforce the value of combined immune and hypoxia-inducible factor 2α inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.